Drugs / FLUAD Quadrivalent
FLUAD Quadrivalent
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07485855 | Dec 2025 → Apr 2027 expected | hematopoietic and lymphoid cell neoplasm, influenza | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT06054269 | Nov 2022 → Jul 2023 | influenza | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04576702 Comparator | Oct 2020 → Mar 2021 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05007041 Comparator | Sep 2021 → Mar 2023 | — | Duke University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLUAD Quadrivalent | “This randomized controlled trial aims to compare the immunogenicity of three influenza vaccine formulations - high-dose trivalent inactivated vaccine (HD-IIV3; Efluelda),...” NCT07485855 ↗ |
| Known as | aIIV4 | “This randomized controlled trial aims to compare the immunogenicity of three influenza vaccine formulations - high-dose trivalent inactivated vaccine (HD-IIV3; Efluelda),...” NCT07485855 ↗ |
| Known as | aQIV | “Eligible participants aged ≥50 years were randomised 1: 1:1:1 to receive aQIVc (n = 116), a non-adjuvanted quadrivalent cell-based influenza vaccine (QIVc; n = 119), an...” PMID 39946829 ↗ Feb 2025 |
| Modality | Vaccine | “Licensed, MF59-Adjuvanted, egg-derived Quadrivalent Influenza Vaccine” NCT04576702 ↗ |
| Route | Intramuscular | “aIIV4 will be administered as a single dose intramuscularly on Day 1” NCT04576702 ↗ |